PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Expression of Matrix Metalloproteinases in Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine Origin.

Abstract Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive tumor entity. Since there is no conventional therapy for advanced PCAC, exploratory treatments are sometimes used. As we previously reported, receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL)/RANK signaling on M2 macrophages promotes the production of chemokines and proinflammatory cytokines to maintain the immunosuppressive tumor environment of extramammary Paget's disease (EMPD). Since EMPD is a skin adenocarcinoma of apocrine gland origin that expresses high levels of RANKL and matrix metalloproteinase (MMP) 7, and EMPD is associated with the presence of RANK+ M2 macrophages, we hypothesized that tumor-associated macrophages (TAMs) in adenocarcinomas such as PCAC might also express RANKL and MMP7.
PMID
Related Publications

RANK/RANKL/OPG system in the intervertebral disc.

Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease.

Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab.

RANKL-Expressing Ectopic Extramammary Paget's Disease on the Lower Abdomen.

Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways.

Authors

Mayor MeshTerms
Keywords

MMPs

Primary cutaneous apocrine carcinoma

RANK

RANKL

denosumab

tumor-associated macrophages

Journal Title anticancer research
Publication Year Start




PMID- 29277763
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - The Expression of Matrix Metalloproteinases in Receptor Activator of Nuclear
      Factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine Origin.
PG  - 113-120
AB  - Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive tumor
      entity. Since there is no conventional therapy for advanced PCAC, exploratory
      treatments are sometimes used. As we previously reported, receptor activator of
      nuclear factor kappa-B (RANK) ligand (RANKL)/RANK signaling on M2 macrophages
      promotes the production of chemokines and proinflammatory cytokines to maintain
      the immunosuppressive tumor environment of extramammary Paget's disease (EMPD).
      Since EMPD is a skin adenocarcinoma of apocrine gland origin that expresses high 
      levels of RANKL and matrix metalloproteinase (MMP) 7, and EMPD is associated with
      the presence of RANK(+) M2 macrophages, we hypothesized that tumor-associated
      macrophages (TAMs) in adenocarcinomas such as PCAC might also express RANKL and
      MMP7. MATERIALS AND METHODS: We employed immunohistochemical staining of RANKL
      and MMP7 in the lesional skin from five patients with PCAC, and microarray
      analysis of MMPs using human monocyte-derived macrophages. RESULTS: According to 
      DNA microarray analysis, the expression of MMP1 and MMP25 was augmented. The DNA 
      microarray results were verified by using real-time polymerase chain reaction
      (RT-PCR). Immunohistochemical staining of MMP1 and MMP25 as well as chemokine
      (C-C motif) ligand (CCL) 5 in the lesional skin from five patients with PCAC
      showed a substantial number of MMP1-bearing cells and MMP25-bearing cells, as
      well as CCL5-producing cells, that were distributed in the lesional skin.
      CONCLUSION: Our study suggests that the RANKL/RANK pathway contributes to the
      development and maintenance of the immunosuppressive tumor microenvironment and
      denosumab may be a promising adjuvant therapy targeting TAMs in cancer of
      apocrine origin.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kambayashi, Yumi
AU  - Kambayashi Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Fujimura, Taku
AU  - Fujimura T
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan [email protected]
FAU - Furudate, Sadanori
AU  - Furudate S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Lyu, Chunbing
AU  - Lyu C
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Hidaka, Takanori
AU  - Hidaka T
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Kakizaki, Aya
AU  - Kakizaki A
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Sato, Yota
AU  - Sato Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Tanita, Kayo
AU  - Tanita K
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
FAU - Aiba, Setsuya
AU  - Aiba S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL5)
RN  - 0 (RANK Ligand)
RN  - 0 (TNFSF11 protein, human)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Adenocarcinoma/*metabolism
MH  - Apocrine Glands
MH  - Chemokine CCL5/genetics/metabolism
MH  - Humans
MH  - Macrophages/*metabolism
MH  - Matrix Metalloproteinases/genetics/*metabolism
MH  - RANK Ligand/*metabolism
MH  - Skin Neoplasms/*metabolism
OTO - NOTNLM
OT  - *MMPs
OT  - *Primary cutaneous apocrine carcinoma
OT  - *RANK
OT  - *RANKL
OT  - *denosumab
OT  - *tumor-associated macrophages
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/113 [pii]
AID - 10.21873/anticanres.12198 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):113-120. doi: 10.21873/anticanres.12198.